A late-stage US biotech pursuing the first approved pharmacologic treatment for limbal stem cell deficiency, a blinding ocular surface disease with no approved drug therapy, backed by more than $175 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results